| Date | Time | Source | Headline | Symbol | Company |
| 24/06/2010 | 23:52 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 24/06/2010 | 23:51 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 24/06/2010 | 23:49 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 24/06/2010 | 23:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 24/06/2010 | 23:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 24/06/2010 | 23:44 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 17/06/2010 | 14:00 | Business Wire | Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/06/2010 | 16:45 | Business Wire | Allos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/06/2010 | 14:00 | Business Wire | Allos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/06/2010 | 14:00 | Business Wire | Allos Therapeutics to Present at Four Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/06/2010 | 14:14 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/06/2010 | 14:00 | Business Wire | Allos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/05/2010 | 14:00 | Business Wire | Allos Therapeutics to Present at the Citi Investment Research Global Health Care Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 18/05/2010 | 14:10 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 18/05/2010 | 13:52 | Dow Jones News | Allos Gets Orphan-Drug Designation For Bladder Cancer Drug | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 18/05/2010 | 13:00 | Business Wire | Allos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/05/2010 | 22:53 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/05/2010 | 20:42 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/05/2010 | 21:10 | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/05/2010 | 21:05 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/05/2010 | 21:00 | Business Wire | Allos Therapeutics Reports First Quarter 2010 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/05/2010 | 20:22 | Edgar (US Regulatory) | Confidential Treatment Order (CT ORDER) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 30/04/2010 | 11:06 | Edgar (US Regulatory) | Proxy Statement (definitive) (DEF 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 28/04/2010 | 22:40 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/04/2010 | 22:01 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/04/2010 | 13:00 | Business Wire | Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/04/2010 | 13:00 | Business Wire | Allos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 14/04/2010 | 22:07 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 09/04/2010 | 21:34 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 09/04/2010 | 21:30 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |